RxDoctor Payments Data

Edward Frederickson, MD

Internal Medicine · Clayton, GANPI 1386710085

Payments from drug & device makers

$1,692in general payments, 2019–2025

Across 86 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$435
  • AbbVie$279
  • Lilly USA, LLC$180
  • Bayer$168
  • Pfizer$98
  • Shire North American Group Inc$75
  • plus $457 from 19 others

What the payments were for

  • Food & beverage$1,65298%
  • Education$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,692 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$265,196
Medicare patients
415
Services billed
5,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft16$424,625
MounjaroTirzepatide281$353,049
OzempicSemaglutide180$261,295
JardianceEmpagliflozin140$200,683
EliquisApixaban166$166,987
TrulicityDulaglutide50$79,993
XareltoRivaroxaban54$69,251
MyrbetriqMirabegron47$39,423
FarxigaDapagliflozin Propanediol40$34,673
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$22,738
Breo ElliptaFluticasone/Vilanterol27$19,377
ProliaDenosumab11$18,798
Nucynta ErTapentadol Hcl13$17,750
Lagevrio (Eua)Molnupiravir32$16,866
Tresiba Flextouch U-100Insulin Degludec14$15,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$180$433,041331 claims
Novo NordiskOzempic$435$261,295180 claims
Boehringer IngelheimJardiance$11$200,683140 claims
PfizerEliquis, Premarin$98$174,373187 claims
AstraZenecaFarxiga, Symbicort$31$45,57961 claims
GSKTrelegy Ellipta, Breo Ellipta$20$42,11549 claims
AbbVieLinzess, Synthroid$279$15,56393 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Clayton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →